US Oncology Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: The Woodlands TX United States (1992)
Status: Acquired by McKesson (2010)

Organization Overview

First Clinical Trial
2003
NCT00254163
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Illinois Cancer Specialists - US Oncology | US Oncology Research, LLC; Ocala Oncology Center | US Oncology Research, McKesson Specialty Health

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 3)

Colorectal Neoplasms (Phase 3)

Fatigue (Phase 2)

Hypersensitivity (Phase 3)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)

Leukemia, Lymphoid (Phase 3)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 3)

Lymphoma, Follicular (Phase 3)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Mucositis (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 3)

Pancreatic Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 2)

Rectal Neoplasms (Phase 2)

Stomatitis (Phase 2)

Triple Negative Breast Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 33
  • # of Trial APIs: 44